Cubicin and Fluid overload - a phase IV clinical study of FDA data

Summary:

Fluid overload is reported as a side effect among people who take Cubicin (daptomycin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Hydrocortisone, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Fluid overload when taking Cubicin. It is created by eHealthMe based on reports of 7,953 people who have side effects when taking Cubicin from the FDA, and is updated regularly.

What is Cubicin?

Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.

What is Fluid overload?

Fluid overload (too much fluid in the blood) is found to be associated with 1,023 drugs and 1,051 conditions by eHealthMe. Check the latest studies of Fluid overload.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

7,953 people reported to have side effects when taking Cubicin.
Among them, 11 people (0.14%) have Fluid overload.

Among these 11 people:

How long have people been on Cubicin when they have Fluid overload? *

What is the gender of people who have Fluid overload when taking Cubicin? *

female: 50 %
male: 50 %

What is the age of people who have Fluid overload when taking Cubicin? *

What are other drugs people take besides Cubicin? *

What are other side effects people have besides Fluid overload? *

Pulmonary Oedema (fluid accumulation in the lungs): 7 people, 63.64%
Pneumonia: 5 people, 45.45%
Respiratory Distress (difficulty in breathing): 4 people, 36.36%
Pleural Effusion (water on the lungs): 4 people, 36.36%
Blood Creatinine Increased: 4 people, 36.36%
Sepsis (a severe blood infection that can lead to organ failure and death): 3 people, 27.27%
Eosinophilic Pneumonia (eosinophil accumulates in the lung): 2 people, 18.18%
International Normalised Ratio Increased: 2 people, 18.18%
Hypotension (abnormally low blood pressure): 2 people, 18.18%
Haemoglobin Decreased: 2 people, 18.18%

What are the existing conditions these people have? *

Enterococcal Sepsis: 2 people, 18.18%
Enterococcal Bacteraemia (presence of bacteria lactic acid in the blood): 2 people, 18.18%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 18.18%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 9.09%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 9.09%
Osteomyelitis (infection of bone): 1 person, 9.09%
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 1 person, 9.09%
Enterococcal Infection: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cubicin and have Fluid overload?

- Check whether Fluid overload is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cubicin:

Cubicin (7,991 reports)

Fluid overload treatments and more:

Fluid overload (20,385 reports)

Browse all side effects of Cubicin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid overload:

Fluid overload (1,023 drugs)

Browse all the conditions that are associated with Fluid overload:

Fluid overload (1,051 conditions)

Related publications that referenced our studies

Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on daptomycin (the active ingredients of Cubicin) and Cubicin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.